Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 185

1.

Noncoding RNAs connect genetic risk factors to the neurodevelopmental basis of bipolar disorder.

Bavamian S, Mellios N, Lalonde J, Fass DM, Wang J, Sheridan SD, Madison JM, Zhou F, Rueckert EH, Barker D, Perlis RH, Sur M, Haggarty SJ.

Mol Psychiatry. 2015 May;20(5):548. doi: 10.1038/mp.2015.51. No abstract available.

PMID:
25921437
2.

The feasibility of using electronic clinical outcome assessments in people with schizophrenia and their informal caregivers.

Tolley C, Rofail D, Gater A, Lalonde JK.

Patient Relat Outcome Meas. 2015 Mar 26;6:91-101. doi: 10.2147/PROM.S79348. eCollection 2015.

3.

Dysregulation of miR-34a links neuronal development to genetic risk factors for bipolar disorder.

Bavamian S, Mellios N, Lalonde J, Fass DM, Wang J, Sheridan SD, Madison JM, Zhou F, Rueckert EH, Barker D, Perlis RH, Sur M, Haggarty SJ.

Mol Psychiatry. 2015 May;20(5):573-84. doi: 10.1038/mp.2014.176. Epub 2015 Jan 27.

PMID:
25623948
4.

Engineered calcium-precipitable restriction enzyme.

Hendrix J, Read T, Lalonde JF, Jensen PK, Heymann W, Lovelace E, Zimmermann SA, Brasino M, Rokicki J, Dowell RD.

ACS Synth Biol. 2014 Dec 19;3(12):969-71. doi: 10.1021/sb500042m.

PMID:
25524101
5.

Directed evolution of an ultrastable carbonic anhydrase for highly efficient carbon capture from flue gas.

Alvizo O, Nguyen LJ, Savile CK, Bresson JA, Lakhapatri SL, Solis EO, Fox RJ, Broering JM, Benoit MR, Zimmerman SA, Novick SJ, Liang J, Lalonde JJ.

Proc Natl Acad Sci U S A. 2014 Nov 18;111(46):16436-41. doi: 10.1073/pnas.1411461111. Epub 2014 Nov 3.

6.

Store-operated calcium entry promotes the degradation of the transcription factor Sp4 in resting neurons.

Lalonde J, Saia G, Gill G.

Sci Signal. 2014 Jun 3;7(328):ra51. doi: 10.1126/scisignal.2005242.

7.

Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options.

Chue P, Lalonde JK.

Neuropsychiatr Dis Treat. 2014 May 8;10:777-89. doi: 10.2147/NDT.S43404. eCollection 2014. Review.

8.

CD4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies.

Madani N, Princiotto AM, Schön A, LaLonde J, Feng Y, Freire E, Park J, Courter JR, Jones DM, Robinson J, Liao HX, Moody MA, Permar S, Haynes B, Smith AB 3rd, Wyatt R, Sodroski J.

J Virol. 2014 Jun;88(12):6542-55. doi: 10.1128/JVI.00540-14. Epub 2014 Apr 2.

9.

Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist.

Courter JR, Madani N, Sodroski J, Schön A, Freire E, Kwong PD, Hendrickson WA, Chaiken IM, LaLonde JM, Smith AB 3rd.

Acc Chem Res. 2014 Apr 15;47(4):1228-37. doi: 10.1021/ar4002735. Epub 2014 Feb 6. Review.

10.

Crystal structures of HIV-1 gp120 envelope glycoprotein in complex with NBD analogues that target the CD4-binding site.

Kwon YD, LaLonde JM, Yang Y, Elban MA, Sugawara A, Courter JR, Jones DM, Smith AB 3rd, Debnath AK, Kwong PD.

PLoS One. 2014 Jan 28;9(1):e85940. doi: 10.1371/journal.pone.0085940. eCollection 2014.

11.

Phosphorylation of the transcription factor Sp4 is reduced by NMDA receptor signaling.

Saia G, Lalonde J, Sun X, Ramos B, Gill G.

J Neurochem. 2014 May;129(4):743-52. doi: 10.1111/jnc.12657. Epub 2014 Feb 12.

12.

The Tumor-Selective Cytotoxic Agent β-Lapachone is a Potent Inhibitor of IDO1.

Flick HE, Lalonde JM, Malachowski WP, Muller AJ.

Int J Tryptophan Res. 2013 Aug 19;6:35-45. doi: 10.4137/IJTR.S12094. eCollection 2013.

13.

Teaching medical students and residents how to inject local anesthesia almost painlessly.

Farhangkhoee H, Lalonde J, Lalonde DH.

Can J Plast Surg. 2012 Fall;20(3):169-72.

14.

Structure-Based Design and Synthesis of an HIV-1 Entry Inhibitor Exploiting X-Ray and Thermodynamic Characterization.

Lalonde JM, Le-Khac M, Jones DM, Courter JR, Park J, Schön A, Princiotto AM, Wu X, Mascola JR, Freire E, Sodroski J, Madani N, Hendrickson WA, Smith AB 3rd.

ACS Med Chem Lett. 2013 Mar 14;4(3):338-343.

15.

A model of peptide triazole entry inhibitor binding to HIV-1 gp120 and the mechanism of bridging sheet disruption.

Emileh A, Tuzer F, Yeh H, Umashankara M, Moreira DR, Lalonde JM, Bewley CA, Abrams CF, Chaiken IM.

Biochemistry. 2013 Apr 2;52(13):2245-61. doi: 10.1021/bi400166b. Epub 2013 Mar 22.

16.

Wide-awake trapeziectomy: video detailing local anesthetic injection and surgery.

Farhangkhoee H, Lalonde J, Lalonde DH.

Hand (N Y). 2011 Dec;6(4):466-7. doi: 10.1007/s11552-011-9367-z. Epub 2011 Sep 24.

17.

HIV-1 Env gp120 structural determinants for peptide triazole dual receptor site antagonism.

Tuzer F, Madani N, Kamanna K, Zentner I, LaLonde J, Holmes A, Upton E, Rajagopal S, McFadden K, Contarino M, Sodroski J, Chaiken I.

Proteins. 2013 Feb;81(2):271-90. doi: 10.1002/prot.24184. Epub 2012 Oct 26.

18.

Spontaneous rearrangement of the β20/β21 strands in simulations of unliganded HIV-1 glycoprotein, gp120.

Shrivastava IH, Wendel K, LaLonde JM.

Biochemistry. 2012 Oct 2;51(39):7783-93. doi: 10.1021/bi300878d. Epub 2012 Sep 21.

19.

Structure-based design, synthesis, and characterization of dual hotspot small-molecule HIV-1 entry inhibitors.

LaLonde JM, Kwon YD, Jones DM, Sun AW, Courter JR, Soeta T, Kobayashi T, Princiotto AM, Wu X, Schön A, Freire E, Kwong PD, Mascola JR, Sodroski J, Madani N, Smith AB 3rd.

J Med Chem. 2012 May 10;55(9):4382-96. doi: 10.1021/jm300265j. Epub 2012 Apr 23.

20.

Efficient, chemoenzymatic process for manufacture of the Boceprevir bicyclic [3.1.0]proline intermediate based on amine oxidase-catalyzed desymmetrization.

Li T, Liang J, Ambrogelly A, Brennan T, Gloor G, Huisman G, Lalonde J, Lekhal A, Mijts B, Muley S, Newman L, Tobin M, Wong G, Zaks A, Zhang X.

J Am Chem Soc. 2012 Apr 11;134(14):6467-72. doi: 10.1021/ja3010495. Epub 2012 Mar 28.

PMID:
22409428
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk